A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Shanghai JMT-Bio Inc.
Peking University Cancer Hospital & Institute
Mirati Therapeutics Inc.
Fudan University
Rutgers, The State University of New Jersey
Massachusetts General Hospital
Sun Yat-sen University
Fudan University
Tianjin Medical University Cancer Institute and Hospital
University of Kansas Medical Center
Henan Cancer Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Sun Yat-sen University
Fudan University
Sir Run Run Shaw Hospital
Shanghai JMT-Bio Inc.
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Peking University
West China Hospital
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
The First Affiliated Hospital with Nanjing Medical University
Assiut University
University of Bern
Fudan University